[Role of new carbapenems in nosocomial intraabdominal infection].
Complicated intraabdominal infections require surgical intervention and the earliest possible empiric broad-spectrum antibacterial therapy. Doripenem, a broad-spectrum carbapenem, provides coverage of key Gram-negative and positive aerobes and anaerobes encountered in complicated intraabdominal infections. In two trials in patients with complicated intraabdominal infections, doripenem was not inferior to meropenem. Combining the results of the two studies, clinical cure rates at the test-of-cure assessment were 85.9% with doripenem and 85.3% with meropenem. Microbiological cure rates were 84.3% with doripenem and 84.5% with meropenem. Doripenem was more effective in the treatment of patients with Pseudomonas aeruginosa. In conclusion, doripenem is a valuable addition to the options available for the empirical treatment of hospitalized patients with serious intraabdominal infections.
Hospital Universitario 12 de Octubre, Madrid, España. jaguadog@medynet.com
José María
JM
Aguado
D000005:Abdomen; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015780:Carbapenems / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D000077726:Doripenem; D004311:Double-Blind Method; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018461:Soft Tissue Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem